Group 1 - The company is focusing on the promotion of a popular approved formulation for cognitive improvement, with ongoing studies in over 80 hospitals and more than 1,000 cases collected [14][15]. - The company is expanding its product pipeline, particularly in the area of blood glucose control, with expectations for developments in 2025 [17][19]. - The company is assessing the efficacy of its treatments in the disease field, aiming to enhance health span [20][21]. Group 2 - The company is collaborating with partners in Hong Kong to further its strategic initiatives and research [22]. - The company is exploring synergistic effects in its product offerings, particularly with SGLT-21 [18]. - The company has confirmed a significant milestone in its business operations, indicating a strong growth trajectory [12].
一图看懂华领医药-B(02552.HK)2025年半年度报告